Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The MET oncogene is a functional marker of a glioblastoma stem cell subtype.
De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, Patanè M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C. De Bacco F, et al. Among authors: patane m. Cancer Res. 2012 Sep 1;72(17):4537-50. doi: 10.1158/0008-5472.CAN-11-3490. Epub 2012 Jun 26. Cancer Res. 2012. PMID: 22738909 Free article.
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G. Pellegatta S, et al. Among authors: patane m. Sci Transl Med. 2018 Feb 28;10(430):eaao2731. doi: 10.1126/scitranslmed.aao2731. Sci Transl Med. 2018. PMID: 29491184 Free PMC article.
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, Finocchiaro G, Park JJH, Dunn DE, Edwards DS, Damrauer JS, Hudson H, Floyd SR, Ferrone S, Savoldo B, Pellegatta S, Dotti G. Nehama D, et al. Among authors: patane m. EBioMedicine. 2019 Sep;47:33-43. doi: 10.1016/j.ebiom.2019.08.030. Epub 2019 Aug 26. EBioMedicine. 2019. PMID: 31466914 Free PMC article.
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
Anghileri E, Di Ianni N, Paterra R, Langella T, Zhao J, Eoli M, Patanè M, Pollo B, Cuccarini V, Iavarone A, Rabadan R, Finocchiaro G, Pellegatta S. Anghileri E, et al. Among authors: patane m. Cancer Immunol Immunother. 2021 Mar;70(3):831-842. doi: 10.1007/s00262-020-02769-4. Epub 2020 Nov 3. Cancer Immunol Immunother. 2021. PMID: 33140187 Free PMC article.
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.
De Bacco F, Orzan F, Erriquez J, Casanova E, Barault L, Albano R, D'Ambrosio A, Bigatto V, Reato G, Patanè M, Pollo B, Kuesters G, Dell'Aglio C, Casorzo L, Pellegatta S, Finocchiaro G, Comoglio PM, Boccaccio C. De Bacco F, et al. Among authors: patane m. Cell Rep. 2021 Jul 27;36(4):109455. doi: 10.1016/j.celrep.2021.109455. Cell Rep. 2021. PMID: 34320350 Free article.
mTORC1 promotes malignant large cell/anaplastic histology and is a targetable vulnerability in SHH-TP53 mutant medulloblastoma.
Conti V, Cominelli M, Pieri V, Gallotti AL, Pagano I, Zanella M, Mazzoleni S, Pivetta F, Patanè M, Scotti GM, Piras IS, Pollo B, Falini A, Zippo A, Castellano A, Maestro R, Poliani PL, Galli R. Conti V, et al. Among authors: patane m. JCI Insight. 2021 Dec 8;6(23):e153462. doi: 10.1172/jci.insight.153462. JCI Insight. 2021. PMID: 34673573 Free PMC article.
129 results